<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997773</url>
  </required_header>
  <id_info>
    <org_study_id>StenoDC</org_study_id>
    <nct_id>NCT03997773</nct_id>
  </id_info>
  <brief_title>Face-it: Health Promotion for Women With Prior Gestational Diabetes</brief_title>
  <acronym>Face-it</acronym>
  <official_title>Face-it: A Health Promotion Intervention for Women With Prior Gestational Diabetes and Their Families - A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steno Diabetes Center Odense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus Municipality</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense Municipality</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Municipality, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liva Healthcare A/S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project focuses on evaluating a postpartum health promotion intervention among families&#xD;
      where the mother has prior gestational diabetes mellitus (GDM). The intervention focuses on&#xD;
      the individual, family and health system levels. The aim is to increase quality of life and&#xD;
      reduce the risk of type 2 diabetes among women with prior GDM and their families.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Face-it: A Health Promotion Intervention for Women with Prior Gestational Diabetes and their&#xD;
      Families&#xD;
&#xD;
      AIM: The aim of the Face-it project is to increase quality of life and reduce the risk of&#xD;
      type 2 diabetes (T2DM) among women with prior gestational diabetes mellitus (pGDM) and their&#xD;
      families.&#xD;
&#xD;
      BACKGROUND: Women with pGDM are at high risk of developing type 2 diabetes. Partners and&#xD;
      offspring of women with GDM are also at elevated risk of developing type 2 diabetes and&#xD;
      related cardiometabolic conditions. Thus, not only are women with prior GDM at high risk of&#xD;
      T2DM and related cardiometabolic conditions, their children and spouses are as well. Since&#xD;
      the cumulative incidence of T2DM increases substantially within the first five years after&#xD;
      delivery (Kim et al. 2002) there is a strong interest in identifying feasible and effective&#xD;
      interventions in this time-period. Evidence from the state-of-the-art Diabetes Prevention&#xD;
      Program suggests that intensive lifestyle intervention can reduce the risk of T2DM among&#xD;
      women with pGDM (Ratner et al. 2008). However, sustainable changes in such behaviours are&#xD;
      difficult and many women do not follow lifestyle recommendations after delivery (Stage et al.&#xD;
      2004). Given the highly elevated risk in this group, this is a substantial missed opportunity&#xD;
      for health promotion aimed at prevention of T2DM for not only the mother, but the entire&#xD;
      family. It is vital that efforts are based on a thorough understanding of the barriers to&#xD;
      health promoting behaviours and involve carefully tailored solutions to overcome these&#xD;
      barriers. The investigators hypothesise that a health promotion intervention that focuses on&#xD;
      enhancing motivation, health literacy, action competences and social involvement in women&#xD;
      with pGDM and their families will reduce diabetes risk and improve quality of life.&#xD;
&#xD;
      DESIGN: Face-it is a two-arm parallel-group randomised clinical trial with women as the unit&#xD;
      of randomization comparing a health promotion intervention with a usual care control group.&#xD;
&#xD;
      PARTICIPANTS, RECRUITMENT AND ELIGIBILIGY: Women with pGDM will be recruited from obstetric&#xD;
      departments at Aarhus University Hospital (AUH), Odense University Hospital (OUH) or&#xD;
      Rigshospitalet (RH) around 24-40 weeks of pregnancy by a health care professional. To be&#xD;
      eligible for enrolment into the study, women should also be able to provide written informed&#xD;
      consent in Danish. Exclusion criteria is that the participants may not be participating in&#xD;
      other postpartum intervention trials with a possible impact on the Face-it trial. Women with&#xD;
      diabetes identified at baseline will be excluded. Partners of women and the new-born&#xD;
      offspring are also invited to participate in the study. Informed consents are obtained from&#xD;
      1) woman and new-born offspring, including permission to obtain information from the medical&#xD;
      record and blood samples for research biobank (woman only), 2) from partner, including blood&#xD;
      samples for research biobank. A separate consent 3) is obtained for collection of blood for&#xD;
      future biobank. In case of non-participation in the study, women are asked for consent to&#xD;
      collect information from the medical record including health characteristics of woman and&#xD;
      offspring related to pregnancy and birth.&#xD;
&#xD;
      SAMPLE SIZE AND RANDOMISATION: Based on prior studies, a mean difference in BMI after 1 year&#xD;
      between the intervention and control groups for the women of -1.0 kg/m2 and standard&#xD;
      deviation of 2.5 is expected. A sample size of 225 women will be required to detect such a&#xD;
      difference in BMI when using a 2:1 randomisation procedure, a power of at least 80% and type&#xD;
      1 error of 5% (two-sided). The sample size increases to 460 women to allow for assuming 30%&#xD;
      loss to follow-up between baseline and follow-up and another 30% will withdraw during the&#xD;
      prolonged period from recruitment to baseline data collection and randomisation.&#xD;
&#xD;
      1/3 of participants will be randomised to the control group and 2/3 to the intervention&#xD;
      group. The randomization procedure has been generated by an independent statistician and will&#xD;
      be in blocks of 6/9/12/15 with a separate randomization at each of the three recruitment&#xD;
      locations. Allocation will be concealed from both the participant and the investigators, who&#xD;
      have the clinical and research responsibility, until baseline data have been collected,&#xD;
      eligibility confirmed, and participation accepted. However, neither participants nor the&#xD;
      investigators will be blinded to the participants intervention or control status after this&#xD;
      point, but the status will be blinded for the analyst. A randomization list will be kept&#xD;
      securely at the study site by an investigator with clinical responsibility. Both the&#xD;
      intervention and usual care group will be part of the evaluation of the Face-it trial and&#xD;
      therefore invited to baseline and follow-up clinical examinations. Participants will be&#xD;
      informed by a research assistant about whether they have been allocated to the control or&#xD;
      intervention group.&#xD;
&#xD;
      INTERVENTION: The intervention has been developed in a thorough and iterative co-creation&#xD;
      process with health care providers and families, where the mothers has pGDM to ensure that it&#xD;
      is carefully tailored to the needs and challenges of the target group and enhance its&#xD;
      sustainability. The three major components of the intervention are: 1) Health visitors as the&#xD;
      core healthcare providers, 2) digital health technology, and 3) a structured cross-sectoral&#xD;
      communication system in the healthcare system.&#xD;
&#xD;
      CONTROL: Participants in the control group will receive usual care practice, including&#xD;
      recommended glucose control measures 3 months and one year after birth. Participants will&#xD;
      receive advice about a healthy lifestyle according to the national recommendations from the&#xD;
      Danish Health and Medicines Authority . Participants in the control group will be invited to&#xD;
      participate in the health examination at baseline and follow-up and thereby obtain&#xD;
      information about own health when attending the two clinical examinations.&#xD;
&#xD;
      STUDY PROCEDURES AND DATA COLLECTION: There are two study visits planned for each participant&#xD;
      (women with pGDM, her partner and baby). Visit 1 (baseline) will take place 10-14 weeks&#xD;
      postpartum. Visit 2 (follow-up) will take place around 12 months postpartum. The measurements&#xD;
      taken at the visits are dependent on whether the participant is a women with pGDM, partner or&#xD;
      offspring.&#xD;
&#xD;
        -  75g oral glucose tolerance test (OGTT) with measurements of glucose and insulin at 0, 30&#xD;
           and 120 minutes (women with pGDM only)&#xD;
&#xD;
        -  Blood samples including fasting glucose, insulin secretion and insulin sensitivity&#xD;
           Index, hbA1c, plasma lipids/ triglycerides, total cholesterol, HDL, LDL (women with pGDM&#xD;
           and partners)&#xD;
&#xD;
        -  Physical measures. Investigations on women with pGDM and their partners will include&#xD;
           BMI, height, weight, waist- and hip circumference, body fat, blood pressure.&#xD;
&#xD;
        -  Physical measures on offspring will include height, weight, abdominal- and head&#xD;
           circumference (at one-year follow-up).&#xD;
&#xD;
        -  Questionnaire. Detailed information will be collected about socio-demographic and&#xD;
           -economic details, dietary-, physical activity-, and sleep patterns; quality of life,&#xD;
           stress, depression, self-perceived health, health literacy, motivation for behaviour&#xD;
           change, social support, self-efficacy, risk perception and knowledge about diabetes risk&#xD;
           in women with pGDM and their partners. Information about obstetric history and&#xD;
           breastfeeding will also be collected from women with pGDM&#xD;
&#xD;
        -  Objective measures of physical activity and sedentary patterns (subgroup)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-arm parallel design RCT with women with prior GDM as the unit of randomisation comparing a health promotion intervention with a usual care group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Mass Index (BMI) in women with prior GDM</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>To assess changes in BMI, height and body weight will be measured, and calculated kg/m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glucose in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Fasting glucose (both women and partner) and 2h OGTT (women only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>HbA1c measured in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Insulin secretion and insulin sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Systolic and diastolic blood pressure will be measured with the participant in sitting position and with average of three readings measured with two minute intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist- and hip circumference in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Waist circumference will be measured halfway between the lowest point of the costal margin and highest point of the iliac crest; whereas hip circumference will be measured at the level of the greater femoral trochanter. Both will be measured to the nearest 0.5 cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat% in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Body fat% will be measured using body impedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI) in partners</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>To assess changes in BMI, height and body weight will be measured, and calculated kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma lipids/triglycerides, total cholesterol, HDL, LDL</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Blood samples will be drawn after an overnight fast and will include measures of lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Assessed through questionnaire. Quality of life will be measured using the 12-item Short Form Health Survey (SF-12v2). Summary scores will be calculated for both the physical and mental health domains. The SF-12 summary scores range from 0 to 100, with higher scores representing better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in well-being in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Assessed through questionnaire. Well-being will be measured with The WHO-Five Well-being Index (WHO-5). An individual score between 0 (worst possible ) and 100 (best possible) is calculated based on the replies to the five questions in the questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-perceived health in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Assessed through questionnaire. Self-perceived Health will be measured using the question &quot;in general, would you say that your health is excellent, very good, good, fair, or poor?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stress in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Assessed through questionnaire. Stress will be measured with the Perceived Stress Scale (PSS). Individual scores on the PSS ranges from 0 (lowest possible perceived stress level) to 40 (highest possible perceived stress level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dietary patterns in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Assessed through questionnaire. Dietary patterns will be measured using the Dietary Quality Score (DQS-2017). The score is based on questions regarding intake of fruit, vegetables, fish and fats and is rated on a scale from 0 to 8, with 8 being the most optimal diet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity patterns in women with prior GDM and their partner</measure>
    <time_frame>Measured at baseline and at follow-up 1 year postpartum</time_frame>
    <description>Assessed through questionnaire. Physical activity will be measured using adapted version of the International Physical Activity Questionnaire (IPAQ) short form. Physical activity levels will be measured in minutes per week.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive the intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will receive usual care - will be the control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Face-it Intervention</intervention_name>
    <description>The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with a GDM diagnosis according to current Danish guidelines (2h oral glucose&#xD;
             tolerance test â‰¥9.0mmol/l)&#xD;
&#xD;
          -  Women with a GDM diagnosis should also be attending and giving birth at the obstetric&#xD;
             departments at either Aarhus University hospital, Odense University Hospital or&#xD;
             Rigshospitalet&#xD;
&#xD;
          -  Partner or infant of women with a GDM diagnosis&#xD;
&#xD;
          -  Able to provide written informed consent in Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant participation in other postpartum intervention trial with a possible&#xD;
             impact on the participation in the face it trial&#xD;
&#xD;
        Withdrawal Criteria:&#xD;
&#xD;
          -  Participant's withdrawal of the informed consent&#xD;
&#xD;
          -  Safety concerns, judged by the investigator&#xD;
&#xD;
          -  Non-compliance with the protocol, judged by the investigator&#xD;
&#xD;
          -  Woman with pGDM being diagnosed with type 1 or type 2 diabetes before or during the&#xD;
             first examination (baseline data collection visit)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helle Terkildsen Maindal, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inger Dahl-Petersen, MSc, PhD</last_name>
    <phone>004524890764</phone>
    <email>inger.katrine.dahl-petersen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karoline Kragelund Nielsen, MSc, PhD</last_name>
    <phone>004524890764</phone>
    <email>karoline.kragelund.nielsen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mette Rasmussen Bracken</last_name>
    </contact>
    <investigator>
      <last_name>Per Ovesen, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulla Kampmann Opstrup, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vibeke Ladefoged</last_name>
    </contact>
    <investigator>
      <last_name>Peter Damm, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Romancsuk</last_name>
    </contact>
    <investigator>
      <last_name>Dorte Moeller Jensen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002 Oct;25(10):1862-8. Review.</citation>
    <PMID>12351492</PMID>
  </reference>
  <reference>
    <citation>Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008 Dec;93(12):4774-9. doi: 10.1210/jc.2008-0772. Epub 2008 Sep 30.</citation>
    <PMID>18826999</PMID>
  </reference>
  <reference>
    <citation>Stage E, Ronneby H, Damm P. Lifestyle change after gestational diabetes. Diabetes Res Clin Pract. 2004 Jan;63(1):67-72.</citation>
    <PMID>14693414</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Helle terkildsen Maindal</investigator_full_name>
    <investigator_title>Professor, Senior Researcher, MPH, PhD</investigator_title>
  </responsible_party>
  <keyword>Gestational Diabetes</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Family Intervention</keyword>
  <keyword>Denmark</keyword>
  <keyword>Health Promotion</keyword>
  <keyword>Postpartum Intervention</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Wellbeing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

